Q2 2023 Aurobindo Pharma Ltd Earnings Call Transcript
Hello, and good morning. Welcome to Aurobindo Pharma Quarter 2 FY '23 Earnings Call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Deepti Thakur for the opening remarks. Thank you, and over to you.
Thank you, Aditya. Good morning, and a warm welcome to our second quarter FY '23 earnings call. I'm Deepti Thakur from the Investor Relations team. I would like to introduce my senior management team today on the call with us, represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccine and Peptides business; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head Formulations Aurobindo Pharma Limited; Mr. S. Subramanian, CFO; and Mr. Swami Iyer, CEO of Aurobindo Pharma USA.
We will begin the call with summary highlights from the management followed by an interactive Q&A session. Please note that some of the matters we will discuss today are forward-looking, including and without limitations, statements relating to the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |